芦可替尼治疗肝移植后移植物抗宿主病——病例报告及文献综述 - Suppr

Ruxolitinib for Treatment of Graft Versus Host Disease after Liver Transplantation-Case Report and Review of Literature.

作者信息

Gopal Prasanna, Krishnan Sathish Kumar, Sivaprakasam Ponni, Singh Nidhi, Moulee Sampath, Moulee Rajanikanth, Malleeswaran Selvakumar, Varghese Joy, Reddy Mettu S

机构信息

Institute of Comprehensive Liver Care & Transplantation, Star Hospitals, Hyderabad, India.

Liver Transplantation and Hepatobiliary-Pancreatic Surgery, Gleneagles Health City, Chennai, India.

出版信息

J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102583. doi: 10.1016/j.jceh.2025.102583. Epub 2025 Apr 23.

DOI:10.1016/j.jceh.2025.102583

PMID:40511341

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12152622/

Abstract

摘要

相似文献

Ruxolitinib for Treatment of Graft Versus Host Disease after Liver Transplantation-Case Report and Review of Literature.芦可替尼治疗肝移植后移植物抗宿主病——病例报告及文献综述

J Clin Exp Hepatol. 2025 Sep-Oct;15(5):102583. doi: 10.1016/j.jceh.2025.102583. Epub 2025 Apr 23.

Lower incidence of chronic graft--host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft--host disease following allogeneic stem cell transplantation.在异基因干细胞移植后对类固醇难治性急性移植物抗宿主病的治疗中，与单独使用鲁索替尼相比，鲁索替尼联合体外光分离置换术治疗后慢性移植物抗宿主病的发生率更低。

Haematologica. 2025 Jul 1;110(7):1536-1544. doi: 10.3324/haematol.2024.286824. Epub 2025 Mar 20.

Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease.血细胞减少以及鲁索替尼早期与晚期治疗对类固醇难治性急性或慢性移植物抗宿主病患者的影响。

Bone Marrow Transplant. 2025 Jan;60(1):69-78. doi: 10.1038/s41409-024-02445-6. Epub 2024 Nov 6.

Chronic graft-versus-host disease presenting as acute polymyositis: A case series and systematic review.慢性移植物抗宿主病表现为急性多发性肌炎：病例系列和系统评价。

Transpl Immunol. 2022 Feb;70:101520. doi: 10.1016/j.trim.2021.101520. Epub 2021 Dec 22.

Efficacy of Ruxolitinib in the management of chronic GVHD.芦可替尼在慢性移植物抗宿主病管理中的疗效。

Transfus Apher Sci. 2025 Feb;64(1):104053. doi: 10.1016/j.transci.2024.104053. Epub 2024 Dec 17.

Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.慢性移植物抗宿主病治疗随时间的变化：德国、奥地利和瑞士异基因造血干细胞移植中心的15年调查

Transplant Cell Ther. 2025 Jul;31(7):450.e1-450.e10. doi: 10.1016/j.jtct.2025.04.017. Epub 2025 May 5.

Cost-effectiveness of ruxolitinib in Singapore for patients with chronic graft-versus-host disease.

Expert Rev Pharmacoecon Outcomes Res. 2025 Jul 7:1-8. doi: 10.1080/14737167.2025.2529366.

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.芦可替尼治疗对皮质类固醇难治或依赖的慢性移植物抗宿主病患者：III期REACH3研究的3年最终分析

J Clin Oncol. 2025 Jun 25;43(23):JCO2402477. doi: 10.1200/JCO-24-02477.

Acute and chronic graft-versus-host disease treatment and management in the Eastern Mediterranean region: A Worldwide Network for Blood and Marrow Transplantation survey.东地中海地区急性和慢性移植物抗宿主病的治疗与管理：全球血液和骨髓移植网络调查

Hematol Oncol Stem Cell Ther. 2025;18(2):79-85. doi: 10.4103/hemoncstem.HEMONCSTEM-D-25-00005. Epub 2025 Jun 20.

Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease.评估阿沙替利单抗作为慢性移植物抗宿主病的一种治疗选择。

Immunotherapy. 2025 Apr;17(6):409-418. doi: 10.1080/1750743X.2025.2501928. Epub 2025 May 8.

本文引用的文献

Complete resolution of a cutaneous grade 2 graft-versus-host disease after liver transplantation using ruxolitinib.

Clin Transplant. 2021 Aug;35(8):e14366. doi: 10.1111/ctr.14366. Epub 2021 Jun 6.

Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge.肝移植后的移植物抗宿主病：诊断与管理挑战

ACG Case Rep J. 2020 Dec 21;7(12):e00499. doi: 10.14309/crj.0000000000000499. eCollection 2020 Dec.

Early Outcomes of Ruxolitinib in the Treatment of Steroid Refractory Graft-versus-host Disease on Liver Transplant Recipients.

Transplantation. 2020 Aug;104(8):e247. doi: 10.1097/TP.0000000000003252.

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.芦可替尼治疗激素耐药性急性移植物抗宿主病（REACH1）：一项多中心、开放标签的 2 期试验。

Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823.

The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation.芦可替尼在实体器官移植后发生的急性移植物抗宿主病中的应用。

Am J Transplant. 2020 Feb;20(2):589-592. doi: 10.1111/ajt.15579. Epub 2019 Sep 11.

Achievement of Durable and Complete Remission of Graft-versus-host Disease After Liver Transplantation With Ruxolitinib: A Case Report.鲁索替尼治疗肝移植术后移植物抗宿主病实现持久完全缓解：一例报告

Transplantation. 2019 Nov;103(11):e375-e377. doi: 10.1097/TP.0000000000002904.

CARE guidelines for case reports: explanation and elaboration document.病例报告的CARE指南：解释与阐述文件。

J Clin Epidemiol. 2017 Sep;89:218-235. doi: 10.1016/j.jclinepi.2017.04.026. Epub 2017 May 18.

Graft Versus Host Disease After Liver Transplantation in Adults: A Case series, Review of Literature, and an Approach to Management.成人肝移植后的移植物抗宿主病：病例系列、文献综述及管理方法

Transplantation. 2016 Dec;100(12):2661-2670. doi: 10.1097/TP.0000000000001406.

Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.对JAK1/JAK2进行药物阻断可减轻移植物抗宿主病并保留移植物抗白血病效应。

PLoS One. 2014 Oct 7;9(10):e109799. doi: 10.1371/journal.pone.0109799. eCollection 2014.

Graft-versus-host disease after liver transplantation: a comprehensive literature review.肝移植后移植物抗宿主病：全面文献综述。

World J Gastroenterol. 2012 Oct 7;18(37):5240-8. doi: 10.3748/wjg.v18.i37.5240.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ruxolitinib for Treatment of Graft Versus Host Disease after Liver Transplantation-Case Report and Review of Literature.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献